Background/Aims: Innately low hepcidin levels lead to iron overload in HFE-associated hereditary haemochromatosis. Methods: This study compared hepcidin and non-transferrin bound iron (NTBI) levels in untreated iron-loaded and non-iron-loaded C282Y homozygotes to levels in C282Y/H63D compound heterozygotes and individuals with other HFE genotypes associated with less risk of iron overload. Results: As the genotypic risk for iron overload increased, transferrin saturation and serum NTBI levels increased while serum hepcidin levels decreased. Overweight and obese male C282Y homozygotes had significantly higher hepcidin levels than male C282Y homozygotes with a normal BMI. Pearson product-moment analysis showed that serum hepcidin levels significantly correlated with HFE status, serum ferritin, age, NTBI, transferrin saturation, gender and BMI. Subsequent multiple regression analysis showed that HFE status and serum ferritin were significant independent correlates of serum hepcidin levels. Conclusions: In summary, this study has shown that while serum ferritin and HFE status are the most important determinants of hepcidin levels, factors such age, gender, BMI, transferrin saturation and NTBI all interact closely in the matrix of homeostatic iron balance. © 2014 S. Karger AG, Basel

Keywords:
Haemochromatosis, HFE, C282Y homozygote, Hepcidin, Non-transferrin bound iron, Serum ferritin
1.
Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Costy M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten Elshof AE, Gerhard GS, Chorney M: Mutation analysis in hereditary haemochromatosis. Blood Cells Mol Dis 1996;22:187-194.
2.
Feder JN, Gnirke A, Thomas W, Tsuchihashi DA, Ruddy A, Basava F, Dormishan F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee K, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-408.
3.
Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, Morris CP, Walsh TP: Hemochromatosis and HLA-H. Nat Genet 1996;14:249-251.
4.
Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion ML, Yaouang J, Mosser J, Fergelot P, Chauvel B, Bauric P, Carn G, Andrieux N, Gicquel I, Le Gall JY, David V: Hemochromatosis and HLA-H. Nat Genet 1996;14:251-252.
5.
Ryan E, O'Keane C, Crowe J: Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998;24:428-432.
6.
Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Nicoll AJ, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ; Healthiron Study Investigators: HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94-101.
7.
Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA: Disrupted hepcidin regulation in HFE-associated hemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003;361:669-673.
8.
van Dijk BAC, Laarakkers CMM, Klaver SM, Jacobs EMG, van Tits LJH, Janssen MCH, Swinkels DW: Serum hepcidin levels are innately low in HFE- related hemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 2008;142:979-985.
9.
Nicolas G, Chauver C, Viatte L, Danan J, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation. J Clin Invest 2002;110:1037-1044.
10.
Harrison-Findik DD, Schafer D, Klein E, Timchenko NA, Kulaksiz H, Clemens D, Fein E, Andriopoulos B, Pantopoulos K, Gollan J: Alcohol metabolism-mediated oxidative stress down regulates hepcidin transcription and leads to increased duodenal iron-transported expression. J Biol Chem 2006;281:22974-22982.
11.
Miura K, Taura K, Schnabl B, Brenner DA: Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008;48:1420-1429.
12.
Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW: Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650-1669.
13.
Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E, Phung Y, Ganz T, Camaschella C: Blunted response to oral iron challenge in HFE-related hemochromatosis. Blood 2007;110:4096-4100.
14.
Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C: A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011;96:500-506.
15.
Gutteridge JM, Rowley DA, Griffiths E, Halliwell B: Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin Sci 1985;68:463-467.
16.
Brissot P, Ropert M, Le Lan C, Loréal O: Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012;1820:403-410.
17.
Breuer W, Cabantchik ZI: A fluorescence-based one-step assay for serum non-transferrin bound iron. Anal Biochem 2001;299:194-202.
18.
Jacobs EM, Hendricks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L, Cabantchik ZI, Hider RC, Swinkels DW: Results of an international round robin for the quantification of serum non-transferrin bound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem 2005;341:241-250.
19.
Kroot JJ, Laarakkers CM, Geurts-Moespot A, Grebenchtchikov N, Pickkers P, van Ede A, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW: Immunochemical and mass spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-1579.
20.
Swinkels DW, Girelli D, Laarakkers C, Kroot JJ, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 2008;3:e2706.
21.
Ahmad KA, Ahmann JR, Migas MC, Waheed A, Britton RS, Bacon BR, Sly WS, Fleming RE: Decreased liver hepcidin expression in the HFE knockout mouse. Blood Cells Mol Dis 2002;29:361-366.
22.
Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Veltcamp C, Stremmel W: Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to serum transferrin saturation and to non-transferrin bound iron. Blood 2003;102:371-376.
23.
Gleeson F, Ryan E, Barrett S, Russell J, Crowe J: Hepatic iron metabolism gene expression profiles in HFE- associated hereditary hemochromatosis. Blood Cells Mol Dis 2007;38:37-44.
24.
Grebenchtchikov N, Geurts-Moespot AJ, Kroot J, den Heijer M, Tjalsma H, Swinkels DW, Sweep FG: High sensitivity radioimmunoassay for human serum hepcidin. Br J Haematol 2009;146:317-325.
25.
Lainé F, Jouannolle A-M, Morcet J, Brigand A, Pouchard M, Lafraise B, Mosser J, David V, Deugnier Y: Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005;43:1055-1059.
26.
Desgrippes R, Lainé F, Morcet J, Perrin M, Manet G, Jezequel C, Jacquet EB, Ropert M, Deugnier Y: Decreased iron burden in overweight C282Y homozygous women: putative role of increased hepcidin production. Hepatology 2013;57:1784-1792.
27.
Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.
28.
Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW: Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218-e225.
29.
Department of Health and Children: Developing a policy for women's health. Dublin, Government Publications Office, 1995.
30.
de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ: Non-transferrin bound iron is present in serum of hereditary hemochromatosis heterozygotes. Eur J Clin Invest 2000;30:248-251.
31.
De Feo TM, Fargion S, Duca L, Cesana BM, Boncinelli L, Lozza P, Cappellini MD, Fiorelli G: Non-transferrin bound iron in alcohol abusers, Alcohol Clin Exp Res 2001;25:1494-1499.
32.
Le Lan C, Lorél O, Cohen T, Ropert M, Glickenstein H, Lainé F, Pouchard M, Deugnier Y, Le Treut A, Breuer W, Cabantchik ZI, Brissot P: Redox active plasma in C282Y/C282Y haemochromatosis. Blood 2005;105:4527-4531.
33.
Lee DH, Liu DY, Jacobs DR Jr, Shin HR, Song K, Lee IK, Kim B, Hider RC: Common presence of non-transferrin bound iron among patients with type 2 diabetes. Diabetes Care 2006;29:1090-1095.
34.
Chua AC, Olynyk JK, Leedman PJ, Trinder D: Non transferrin-bound iron uptake by hepatocytes is increased in HFE knockout mouse model of hereditary haemochromatosis. Blood 2004;104:1519-1525.
35.
Graham RM, Reutens GM, Herbison CE, Delima RD, Chua AC, Olynyk JK, Trinder D: Transferrin receptor 2 mediates uptake of transferrin-bound and non-transferrin bound iron. J Hepatol 2008;48:327-324.
36.
Nemeth E, Tuttle MS, Powelson J, Vaughan MB, Donovan A, McVey Ward D, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.